BioCentury
ARTICLE | Company News

Corvas, Dyax cancer deal

September 20, 2001 7:00 AM UTC

CVAS and DYAX partnered to research, develop and market serine protease inhibitors for cancer. DYAX will use its phage display technology to identify small proteins, peptides and antibodies that bind ...